revista junio 2010 59 española dehumares.de/files/fallbeispiele/spanien3.pdf · revista española...

rev i s taespañola deozonoterapia

junio 2010 59

damage. Therefore these results suggest that ozone,in our experimental conditions, may have a role inthe treatment of diabetic complications. Other worksstudying the effects of ozone on diabetic patients withmacroangiophatic complications are in progress.

ACKNOWLEDGEMENTSThese studies were supported in part by Randox Laboratories(Antrim, UK) and the Department of Chemistryand Medical Biochemistry, University of Milan.

REFERENCES1. Rudeman NB, Williamson JR, Brownlee M. Glucose and diabeticvascular disease. FASEB J 1992; 6: 2905–'9614.2. Williamson JR, Chang K, Frangos M, Hassan KS, Ido Y,Kawamura T, Nyengoard JR, Van Den Enden M, Kilo C,Tilton RG. Hyperglycemic pseudo hypoxia and diabetic complications.Diabetes 1993; 42: 801–'9613.3. Lin SJ, Hong CY, Chang MS, Chiang BN, Chien S. Increasedaor t ic endothel ial cel l death and enhanced trans-endothel ialmacromolecular transport in streptozotocin-diabetic rats. Diabetología1993; 36: 926–'9630.4. Sinclair AJ, Lunce J. Free radicals, oxidative stress and diabetesmellitus. In: Immunopharmacology of free radical species. BlakeD, Wingard PG, eds. New York: Academic Press, 1995: 183–'9698.5. Cameron NE, Cotter A. The relationship of vascular changes tometabolic factors in diabetes mellitus and their role in the developmentof peripheral nerve complications. Diabetes Metab Rev1994; 10: 189–'96224.6. León OS, Menéndez S, Merino N, Castillo R, Sam S, Pérez L,Cruz E, Bocci V. Ozone oxidative preconditioning: a protectionagainst cellular damage by free radicals. Mediators Inflammation1998; 7: 289–'9694.7. Peralta C, León OS, Xaus C, Prats N, Candelario-Jalil E, Sala-Planell E, Puig-Parellada P, Gelpí E, Roselló-Catafau J. Protectiveeffect of ozone treatment on the injury associated with hepaticischemia-reperfusion: antioxidant–'96prooxidant balance. Free RadicRes 1999; 31: 191–'966.8. Barber E, Menéndez S, León OS, Barber MO, Merino N,Calunga JL, Cruz E, Bocci V. Prevention of renal injury afterinduction of ozone tolerance in rats submitted to warm ischemia.Mediators Inflammation 1999; 8: 37–'9642.9. Peralta C, Xaus C, Bartrons R, León OS, Gelpí E, Roselló-Catafau J. Effect of ozone treatment on reactive oxygen speciesand adenosine production during hepatic isc hemia-reperfusion.Free Radic Res 2000; 33: 595–'96605.10. Hernández F, Menéndez S,Wong R. Decrease of blood cholesteroland stimulation of antioxidative response in cardiopathy patientstreated with endovenous ozone therapy. Free Radic Biol Med1995; 19: 115–'969.11. EL-Kashaeaf HA, Salem HA, Said SA, EL-Mazar Mal. Effect ofpraziquantel on serum glucose and insulin levels in normal andhyperglycemic rats. Arzneim-Forsch 1996; 46: 433–'965.12. Kedziora-Kornatowska KZ, Luciak M, Blaszczyk Y, Pawlak W.Effect of aminoguadin on erythrocyte lipid peroxidation and activitiesof ant ioxidant enzymes in experimental diabetes. Cl in ChemLab Med 1998; 36: 771–'965.13. Mannheim B. Biochemica information. A revised biochemical referencesource. Enzymes for routine, 1st edn. Germany: BoehringerMannheim, 1987: 15–'966.

14. Esterbauer H, Cheeseman KH. Determination of aldehydic lipidperoxidat ion product : malonaldehyde and 4-hydroxynonenal .Methods Enzymol 1990; 186: 407–'9621.15. Bradford MM. A rapid and sensitive method for the quantitationof microgram quantities of protein utilising the principleof protein-dye binding. Anal Bioc hem 1976; 72: 248–'9654.16. Sedlak J, Lindsay RH. Estimation of total protein-bound andnonprotein sulfhydryl groups in tissue with Ellman’'92s reagent. AnalBiochem 1968; 25: 192–'96205.17. Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Determinationof nitrate and nitrite in biological samples using bacterial nitratereductase coupled with the Griess reaction. Methods CompMethods Enzymol 1995; 7: 78–'9683.18. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capellére-Bladin C, Nguyen A, Canteloup S, Dayer JM, Yungers P,Diueke T, Descamps-Latscha B. Advanced oxidation proteinproducts as novel mediators of inflammation and monocytesactivation in chronic renal failure. J Immunol 1998; 161: 2524–'9632.19. Thorme J, Munch G, Muller R, Schinzel R, Kornhuber J, Blum-Degen D, Sitzmann L, Rosler M, Heidlend A, Riederer P.Advanced Glucation End-products associated parameters in theperiphereal blood of patients with Alzheimer’'92s disease. Life Sci1996; 59: 679–'9685.20. Colowick SP, Kaplan NO. Reparation and assays of enzymes.Aldose reductase. In: Methods in enzymology. Hers HG, ed.Berlin: Springer-Verlag, 1962: 333–'965.21. West IC. Radicals and oxidative stress in diabetes. Diabet Med2000; 17: 171–'9680.22. Yoshida K, Hirokawa J, Tagani S, Kawakani Y, Urata Y, Kondo T.Weakened cellular scavenging activity against oxidative stress indiabetes mellitus: regulation of glutathione synthesis and efflux.Diabetologia 1995; 38: 201–'9610.23. Chang KC, Chung SY, Chong WS, Suh JS, Kim SH,Noh HK, Seong BW, Ko HJ, Chun KW. Possible superoxideradical-induced alteration of vascular reactivity in aortas fromstreptozotocin-treated rats. J Pharmacol Exp Ther 1993; 266:992–'961000.24. Elgawish A, Glomb M, Friedlander M, Monnier VM. Involvementof hydrogen peroxide in collagen cross-linking by high glucose invitro and in vivo. J Biol Chem 1996; 271: 12964–'9671.25. Cameron NE, Cotter MA. Neurovascular dysfunction in diabeticrats. J Clin Invest 1995; 96: 1159–'9663.26. Chávez ME. Hacia la comprensión de la endoteliopatía diabética.Can Actualidades Terapéuticas 1997; 3: 17–'9624.27. Cameron NE, Cotter MA, Dines KC, Maxifield EK. Pharmacologicalmanipulation of vascular endothelium in non-diabetic andstreptozotocin-diabetic rats: effects on nerve conduction, hypoxicresistance and endoneurial capillarization. Diabetologia 1993; 36:516–'9622.28. Guiliano D, Cerieloo A, Paolisso G. Oxidative stress and diabeticvascular complicat ions. Diabetes Care 1996; 19: 257–'9667.29. Pieper GM, Dembny K, Siebeneich W. Long-term treatmentin vivo with NOX-101, a scavenger of nitric oxide, preventsdiabetes-induced endiothelial dysfunction. Diabetología 1998; 41:1220–'966.

rev i s taespañola deozonoterapia

junio 2010 60

artículos internacionalesozono más cobaltoterapia en pacientescon adenocarcinoma prostático

rev i s taespañola deozonoterapia

junio 2010 61

rev i s taespañola deozonoterapia

junio 2010 62

rev i s taespañola deozonoterapia

junio 2010 63

rev i s taespañola deozonoterapia

junio 2010 64

artículos internacionalesresults of a non-specific immunomodulationtherapy in chronic heart failure (ACCLAIM trial):a placebo-controlled randomised trial.

rev i s taespañola deozonoterapia

junio 2010 65

rev i s taespañola deozonoterapia

junio 2010 66

rev i s taespañola deozonoterapia

junio 2010 67

rev i s taespañola deozonoterapia

junio 2010 68

rev i s taespañola deozonoterapia

junio 2010 69

rev i s taespañola deozonoterapia

junio 2010 70

rev i s taespañola deozonoterapia

junio 2010 71

rev i s taespañola deozonoterapia

junio 2010 72

rev i s taespañola deozonoterapia

junio 2010 73

artículos internacionalesozone therapy in cancer treatment:state of the art.

rev i s taespañola deozonoterapia

junio 2010 74

rev i s taespañola deozonoterapia

junio 2010 75

rev i s taespañola deozonoterapia

junio 2010 76

rev i s taespañola deozonoterapia

junio 2010 77

rev i s taespañola deozonoterapia

junio 2010 78

rev i s taespañola deozonoterapia

junio 2010 79

patrocinadores del número

rev i s taespañola deozonoterapia

junio 2010 81

patrocinadores del número

www.proteal.com(+34) 902 501 609(+34) 93 163 02 27

proteal@proteal.com

Empresa biotecnológica dedicada a ofrecer, tanto productos como servicios, aplicadosa la regeneración tisular y a la medicina regenerativa.

el número 2 de la revistapróximamente en su correoy en nuestra página web